Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
TA

NASDAQ · TAK

Takeda Pharmaceutical Company Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$18.91

Down-$0.14 (-0.73%)

Updated Sep 20, 2026, 1:02 PM

SID Score

5.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
45.42B
P/E ratio
50.83
Dividend yield
3.50%
52-week range
$12.99 – $19.10
Volume
2.96M
Avg. volume
2.78M

Price performance

TAK price history

1M range · 19 trading sessions · Daily adjusted prices

TAK closed at $18.91 after 19 trading sessions, up 3.67% for the selected period.

Last close
$18.91
Period change
+3.67%
Period low
$17.98
Period high
$19.05
Daily close
View OHLC price history
TAK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$18.80$19.01$18.80$18.912.96M
Sep 17, 2026$19.02$19.10$19.00$19.052.71M
Sep 16, 2026$18.75$18.825$18.595$18.642.95M
Sep 15, 2026$18.74$18.765$18.61$18.702.68M
Sep 14, 2026$18.56$18.70$18.54$18.602.36M
Sep 11, 2026$18.38$18.445$18.20$18.262.15M
Sep 10, 2026$18.34$18.34$18.10$18.111.75M
Sep 9, 2026$18.18$18.35$18.1472$18.211.57M
Sep 8, 2026$18.53$18.65$18.28$18.323.14M
Sep 4, 2026$18.48$18.54$18.385$18.451.5M
Sep 3, 2026$18.75$18.835$18.52$18.712.85M
Sep 2, 2026$18.30$18.495$18.275$18.431.72M
Sep 1, 2026$18.18$18.405$18.18$18.231.9M
Aug 31, 2026$17.99$18.06$17.955$17.981.78M
Aug 28, 2026$18.00$18.11$17.96$18.031.81M
Aug 27, 2026$18.21$18.22$17.971$18.031.73M
Aug 26, 2026$18.32$18.38$18.2191$18.232.33M
Aug 25, 2026$18.21$18.355$18.21$18.351.25M
Aug 24, 2026$18.24$18.26$18.11$18.242.23M

Latest TAK news

The latest Smart Investors Daily articles mentioning TAK.

Stock researchCompany · Overview

TAK research

Overview

Company profile and research snapshot.

Company profile

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TAK recent ratings
DateFirmRatingTarget
Mar 11, 2020JP MorganOverweight—
Nov 1, 2019Cowen & Co.Market Perform—
Sep 24, 2019JefferiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

OSAKA, Japan & CAMBRIDGE, Mass., September 18, 2026--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifti

Yahoo · Sep 17, 2026

Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date falls in the first quarter of calendar 2027, creating a defined regulatory window for the investigational once-daily oral treatment. Zasocitinib inhibits tyrosine kinase […]

Yahoo · Sep 16, 2026

Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?

Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same time, bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices and administrative requirements. We’ll now examine how...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By